Louisiana 2019 Regular Session

Louisiana House Bill HB526

Introduced
3/29/19  
Refer
3/29/19  
Refer
3/29/19  
Refer
4/8/19  
Report Pass
5/1/19  
Engrossed
5/16/19  
Refer
5/20/19  

Caption

Prohibits the imposition of prior authorization requirements in Medicaid managed care organizations for certain prescription medications used in treating opioid use disorder (RE DECREASE SG RV See Note)

Impact

If enacted, HB 526 could significantly impact the state's approach to treating opioid use disorder. By removing restrictions on prior authorization and prescribing authority, it aims to streamline the process for patients seeking necessary medication. This legislative change reflects an understanding of the urgent need for accessible treatment options amid the ongoing opioid crisis, potentially improving health outcomes for individuals affected by addiction. Additionally, it aligns Louisiana's Medicaid policies with best practices for public health pertaining to addiction treatment.

Summary

House Bill 526 aims to enhance access to vital medications for the treatment of opioid use disorder by prohibiting certain restrictive requirements imposed by Medicaid managed care organizations. Notably, the bill eliminates prior authorization and step therapy requirements for FDA-approved medications used to treat opioid use disorder, allowing healthcare providers greater flexibility in prescribing these necessary treatments. Further, it requires that at least two formulations of buprenorphine/naloxone remain available on the Louisiana Medicaid Single Preferred Drug List, ensuring that patients have access to effective medication-assisted treatments.

Sentiment

The general sentiment surrounding HB 526 appears to be positive, particularly among advocates for addiction treatment and mental health services. Supporters view the bill as a necessary reform that could facilitate better access to treatment for those struggling with opioid addiction. However, there may be some concern about the implications for managed care organizations and their ability to manage costs effectively while complying with the new regulations. Overall, the bill is perceived as a proactive response to a pressing public health issue.

Contention

Despite its mostly favorable reception, there are points of contention regarding the potential impact on healthcare costs and treatment standards. Some stakeholders in the healthcare community may raise concerns about the implications of loosened prescribing restrictions, fearing it could lead to an over-prescription of medication. The balance between ensuring adequate treatment access and maintaining responsible prescribing practices remains a critical discussion point as the bill moves forward in the legislative process.

Companion Bills

No companion bills found.

Previously Filed As

LA SB1922

Relating to contract requirements for prescription drug benefits provided by Medicaid managed care organizations and a study regarding Medicaid prior authorization requirements for certain prescription drugs.

LA SB323

Public Health - Medications to Treat an Opioid Use Disorder - Preferred and Nonpreferred Medications

LA HR257

Requests the La. Department of Health to study the benefits and costs of eliminating prior authorization requirements for medication-assisted treatment for opioid use disorder

LA HB578

Public Health - Medications to Treat an Opioid Use Disorder - Preferred and Nonpreferred Medications

LA HB393

Provides relative to prescription drug benefits of certain managed care organizations participating in the La. Medicaid coordinated care network program (RE1 INCREASE GF EX See Note)

LA HB2261

HIV medication; prior authorization; prohibition

LA H1379

Exempting medications used for the treatment of opioid use disorder from the prior approval process under the Massachusetts Medicaid program

LA S0786

Prohibits prior authorization or a step therapy protocol for the prescription of a nonpreferred medication on their drug formulary used to assess or treat an enrollee's bipolar disorder, schizophrenia or schizotypal.

LA S2380

Prohibits prior authorization or a step therapy protocol for the prescription of a nonpreferred medication on their drug formulary used to assess or treat an enrollee's bipolar disorder, schizophrenia or schizotypal.

LA HB1558

To Amend The Prior Authorization Transparency Act; And To Modify The Medication-assisted Treatment Under The Prior Authorization Transparency Act.

Similar Bills

UT SB0257

Medicaid Accounts Amendments

UT HB0247

Child Health Care Coverage Amendments

AR SB518

To Amend The Medicaid Fraud Act And The Medicaid Fraud False Claims Act; And To Update Language And Definitions To Reflect Changes Within The Healthcare System;.

AR SB515

To Amend The Medicaid Fraud Act And The Medicaid Fraud False Claims Act.

UT HB0463

Medicaid Funding Amendments

NJ A3334

Requires Medicaid reimbursement for covered behavioral health services provided by local education agency to student who is eligible Medicaid beneficiary.

NJ S2416

Requires Medicaid reimbursement for covered behavioral health services provided by local education agency to student who is eligible Medicaid beneficiary.

NJ S3495

Provides for presumptive eligibility for home and community-based services and services provided through program of all-inclusive care for the elderly under Medicaid.